Hospital readmissions in children with new-onset infantile epileptic spasms syndrome.
hospitalizations
infantile epileptic spasms syndrome
readmissions
Journal
Epilepsia open
ISSN: 2470-9239
Titre abrégé: Epilepsia Open
Pays: United States
ID NLM: 101692036
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
12
01
2023
accepted:
09
02
2023
medline:
5
6
2023
pubmed:
16
2
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
To describe inpatient resource use in the 2 years following infantile epileptic spasms syndrome (IESS) diagnosis, examine the association between clinical/demographic variables and incidence of readmission, and identify risk factors/reasons for frequent readmissions. Retrospective cohort analysis of readmissions (scheduled/unscheduled) within the first 2 years following IESS diagnosis, details of readmissions (number/time between rehospitalizations, and length of stay), demographic/clinical variables, and reasons for readmissions were collected. Negative binomial regression analysis evaluated associations between incidence of readmissions (both scheduled/unscheduled and unscheduled alone) and demographic/clinical factors. Logistic regression assessed the risk of having recurrent readmissions (≥5 readmissions). Among 93 (60% males) new-onset IESS patients, there were 394 readmissions (56% scheduled and 44% unscheduled) within 2-years following IESS diagnosis. Mean length of stay was 3.5 days (SD: 5.9). Readmissions occurred in 82 patients (88%) and 37 (40%) experienced ≥5 readmissions. On multivariate regression analysis, readmissions were increased with use of multiple first-line treatments for IESS (P = 0.006), technology assistance (P ≤ 0.001), and multispecialty care (P = 0.01); seizure freedom (P = 0.015) and known etiology (P = 0.011) lowered the incidence of readmissions. Examining unscheduled readmissions separately, increased readmissions occurred with public insurance (P = 0.013), technology use (P ≤ 0.0.001), and multispecialty care (P = 0.013); seizure freedom decreased unscheduled readmissions (P = 0.006). Technology assistance (G-tube, NG tube, VP shunt, and tracheostomy use) increased the odds (P = 0.007) for recurrent readmissions. Reasons for readmissions included EEG monitoring (protocol driven for verification of IESS remission/characterization of events/EEG surveillance/presurgical monitoring) (51%), acute medical issues (21%), and seizure exacerbation (15%). Protocol-driven readmissions declined an estimated 52% following protocol modification during the study. In the 2 years following IESS diagnosis, there is substantial inpatient resource use with nearly 40% experiencing ≥5 readmissions (mostly epilepsy related). Since readmissions are increased by intrinsic patient characteristics such as medical complexity (technology use and multispecialty care) or epilepsy-related issues, the preventability of readmissions is uncertain, except for protocol-driven ones.
Identifiants
pubmed: 36790214
doi: 10.1002/epi4.12711
pmc: PMC10235577
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
444-455Informations de copyright
© 2023 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.
Références
Epileptic Disord. 2004 Mar;6(1):31-40
pubmed: 15075066
J Perinatol. 2018 Jun;38(6):734-741
pubmed: 29449613
Epilepsia. 2018 Dec;59(12):2231-2239
pubmed: 30395353
Hosp Pediatr. 2015 Nov;5(11):602-4
pubmed: 26526809
Neurology. 2018 Jan 9;90(2):67-73
pubmed: 29247076
Pediatr Neurol. 2019 Apr;93:11-16
pubmed: 30704869
Epilepsia. 2010 Oct;51(10):2175-89
pubmed: 20608959
JAMA. 2013 Jan 23;309(4):372-80
pubmed: 23340639
Epilepsia. 2016 Nov;57(11):1834-1842
pubmed: 27615012
Epilepsy Res. 2021 Oct;176:106733
pubmed: 34333373
Pediatr Neurol. 2019 Oct;99:16-22
pubmed: 31331669
Neurology. 2019 Apr 16;92(16):e1926-e1932
pubmed: 30894440
Epilepsia. 2022 Jun;63(6):1349-1397
pubmed: 35503712
Epilepsy Res. 2014 Mar;108(3):576-86
pubmed: 24447611
JAMA. 2011 Feb 16;305(7):682-90
pubmed: 21325184
J Pediatr. 2011 Aug;159(2):284-90
pubmed: 21429511
Epilepsia Open. 2021 Dec;6(4):714-719
pubmed: 34524734
Epilepsia Open. 2018 Oct 23;3(Suppl Suppl 2):143-154
pubmed: 30564773
Pediatr Neurol. 2020 Mar;104:23-29
pubmed: 31911027
Epilepsia. 2011 Apr;52(4):746-52
pubmed: 21320111
Epilepsia. 2016 Mar;57(3):455-63
pubmed: 26785359
Dev Med Child Neurol. 2001 Oct;43(10):658-67
pubmed: 11665822
Pediatr Neurol. 2003 Apr;28(4):285-91
pubmed: 12849882
PLoS Med. 2012 Jan;9(1):e1001158
pubmed: 22272190
Adv Ther. 2016 Aug;33(8):1293-304
pubmed: 27324137
Epilepsia. 2015 Aug;56(8):1185-97
pubmed: 26122601
J Perinatol. 2022 May;42(5):624-630
pubmed: 34815520
J Child Neurol. 2016 Feb;31(2):164-9
pubmed: 25999302
Epilepsia Open. 2023 Jun;8(2):444-455
pubmed: 36790214
Pediatrics. 2010 Oct;126(4):647-55
pubmed: 20855394
Minerva Pediatr. 2020 Jun 05;:
pubmed: 32508074
Dev Med Child Neurol. 2012 Oct;54(10):938-44
pubmed: 22845753
Pediatr Neurol. 2018 May;82:13-18
pubmed: 29610033
Lancet Neurol. 2005 Nov;4(11):712-7
pubmed: 16239177
Epilepsia. 2012 Feb;53(2):291-300
pubmed: 22221191
Lancet Child Adolesc Health. 2018 Oct;2(10):715-725
pubmed: 30236380
Epilepsy Behav. 2014 Mar;32:135-41
pubmed: 24561658
Pediatr Neurol. 2020 Jul;108:93-98
pubmed: 32299746
BMJ. 2002 Oct 26;325(7370):961-4
pubmed: 12399352
J Pediatr. 2004 Jun;144(6):799-803
pubmed: 15192629
Epilepsia. 2010 May;51(5):874-82
pubmed: 20002149
Epilepsia. 2008 Sep;49(9):1504-9
pubmed: 18410363